The Motley Fool on MSN54m
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming SoonIn the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results